Intervention Review

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

  1. Pan Feng Shang1,
  2. Joey Kwong2,
  3. Zhi Ping Wang3,
  4. Jinhui Tian4,
  5. Lei Jiang4,
  6. KeHu Yang4,
  7. Zhong Jin Yue1,*,
  8. Jun Qiang Tian4

Editorial Group: Cochrane Urology Group

Published Online: 11 MAY 2011

Assessed as up-to-date: 31 MAR 2010

DOI: 10.1002/14651858.CD006885.pub2


How to Cite

Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, Yue ZJ, Tian JQ. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD006885. DOI: 10.1002/14651858.CD006885.pub2.

Author Information

  1. 1

    Second Hospital of Lanzhou University, Department of Urology, Lanzhou City, Gansu, China

  2. 2

    London School of Hygiene & Tropical Medicine, Department of Non-Communicable Disease Epidemiology, London, UK

  3. 3

    Second Hospital of Lanzhou University, Institute of Urology, Lanzhou City, Gansu, China

  4. 4

    Lanzhou University, Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou City, Gansu, China

*Zhong Jin Yue, Department of Urology, Second Hospital of Lanzhou University, No. 82, Cui Ying Men Street, Lanzhou City, Gansu, 730030, China. yuezhongjin@yahoo.com.cn.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 11 MAY 2011

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jason A. Efstathiou, Anthony L. Zietman, Clinical Radiation Oncology, 2016,

    CrossRef

  2. 2
    Rianne J.M. Lammers, Joan Palou, Wim P.J. Witjes, Maria H.D. Janzing-Pastors, Christien T.M. Caris, J. Alfred Witjes, Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy, BJU International, 2014, 114, 2
  3. 3
    Tao Zhang, Shanna Qu, Qi Shi, Dalin He, Xunbo Jin, Evodiamine Induces Apoptosis and Enhances TRAIL-Induced Apoptosis in Human Bladder Cancer Cells through mTOR/S6K1-Mediated Downregulation of Mcl-1, International Journal of Molecular Sciences, 2014, 15, 2, 3154

    CrossRef

  4. 4
    Johannes Falke, Rianne J.M. Lammers, Harm C. Arentsen, Miroslav Ravic, Raffaella Pozzi, Erik B. Cornel, Henk Vergunst, Theo M. de Reijke, J. Alfred Witjes, Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer, The Journal of Urology, 2013, 189, 6, 2077

    CrossRef

  5. 5
    Joshua G. Griffin, Jeff Holzbeierlein, Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects, Urologic Clinics of North America, 2013, 40, 2, 197

    CrossRef

  6. 6
    Stefanie Schmidt, Frank Kunath, Bernadette Coles, Desiree Louise Draeger, Laura-Maria Krabbe, Rick Dersch, Katrin Jensen, Philipp Dahm, Joerg J Meerpohl, Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer, The Cochrane Library,
  7. 7
    Ahmet Gudeloglu, Halil Kiziloz, Molly M Neuberger, Gretchen M Kuntz, Philipp Dahm, Intravesical electromotive drug administration for non-muscle invasive bladder cancer, The Cochrane Library,